AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Humacyte, Inc. Director's Dealing 2025

Jun 16, 2025

33410_dirs_2025-06-16_e752abb8-6d41-403a-96f3-7ac7139c5c2f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2025-06-12

Reporting Person: Seimetz Diane (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-12	Stock Options (right to buy)	$2.41	A	80000	Acquired	2035-06-12	Common Stock (80000)	Direct

Footnotes

F1: The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.